Skip to main content
padlock icon - secure page this page is secure


Buy Article:

$52.00 + tax (Refund Policy)


1. The aim of the present study was to assess the efficacy of pseudoephedrine in coryza.

2. In a double-blind, randomized, placebo-controlled design, 48 adults with acute coryza received a single oral dose of 60 mg pseudoephedrine (Sudafed™; Pfizer Consumer HealthCare Group, Caringbah, NSW, Australia) or matching placebo. Before and after dosing, nasal airway resistance (NAR), nasal volume, the minimum intranasal cross-sectional area (MCA) and the symptom of nasal congestion were measured.

3. Pseudoephedrine produced a significant decrease in NAR (P = 0.005; 95% confidence interval (CI) 0.073, 0.383). Nasal volume increased, but this did not reach significance (P = 0.07; 95% CI −0.842, 0.034). There was no change in MCA and symptoms.

4. In conclusion, pseudoephedrine has a moderate effect in decreasing objective measures of nasal congestion in coryza.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: acoustic rhinometry; clinical trial; coryza; human; placebo; pseudoephedrine; rhinomanometry

Document Type: Research Article

Affiliations: Rhinometrica Cold Study Unit, Adelaide Research & Innovation, Department of Clinical and Experimental Pharmacology, University of Adelaide, Adelaide, South Australia, Australia

Publication date: July 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more